Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Mankind Pharma
Deal Size : $12.1 million
Deal Type : Financing
Details : ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Brand Name : ACM-001.1
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : Pindolol
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Mankind Pharma
Deal Size : $12.1 million
Deal Type : Financing
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : S-oxprenolol is the second in a new class of anabolic-catabolic transforming agents (ACTAs) under development by Actimed and this newest patent completes the global patent estate relating to the treatment of ALS with S-oxprenolol.
Brand Name : ACM-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2021
Lead Product(s) : Pindolol
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Actimed Therapeutics Successfully Closed of £2.5m Extended Seed B Funding Round
Details : The proceeds will allow Actimed to further advance the development of its lead compound, S-pindolol (ACM-001.1), for cancer cachexia, by performing a Pharmacokinetic (PK) and Pharmacodynamic (PD) study due to start later this year.
Brand Name : ACM-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 10, 2021
LOOKING FOR A SUPPLIER?
Reset All
